National Multiple Sclerosis Society: Paper Provides More Details of Impacts of Gilenya in Children With MS
March 12, 2020
March 12, 2020
NEW YORK, March 12 -- The National Multiple Sclerosis Society issued the following news:
Additional results have been published from the clinical trial of Gilenya(R) (fingolimod, Novartis AG) in children with MS, showing it could slow the rate of brain tissue loss and reduce other signs of disease activity as observed on MRI (magnetic resonance imaging) scans significantly more than interferon beta-1a (Avonex(R)). Based on this phase 3 trial, Gilenya is approved to treat children an . . .
Additional results have been published from the clinical trial of Gilenya(R) (fingolimod, Novartis AG) in children with MS, showing it could slow the rate of brain tissue loss and reduce other signs of disease activity as observed on MRI (magnetic resonance imaging) scans significantly more than interferon beta-1a (Avonex(R)). Based on this phase 3 trial, Gilenya is approved to treat children an . . .